Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Transplant ; 30(1): 26-32, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26448343

ABSTRACT

AIM: Patent foramen ovale (PFO) is a common atrial septal defect that is largely asymptomatic and often undiagnosed. The impact of a PFO in patients undergoing liver transplantation (LT) is unknown. OBJECTIVE: Assess the impact of PFO and physiologic intrapulmonary shunt (IPS) on the perioperative outcomes of patients who underwent LT. METHODS: We performed a retrospective, intention-to-treat analysis of patients with PFO and controls without PFO who underwent LT at Mayo Clinic in Florida between 2008 and 2013. Patients with physiologic IPS were also analyzed. The cohorts were compared for baseline characteristics, length of stay in the intensive care unit (ICU), postoperative oxygen requirements, 30-d cerebrovascular accidents, and mortality. RESULTS: Of the 935 patients who underwent LT, 10.4% had proven PFO by pre-LT echocardiogram. Control patients (n = 101) were statistically older than PFO and IPS (n = 56) patients, but similar in sex, BMI, Model for End-stage Liver Disease score, American Society of Anesthesiologist score, and left ventricular ejection fraction. PFO and IPS patients had similar length of stay in the ICU, mechanical ventilation times, post-LT oxygen requirements, and 30-d mortality compared to controls. Subgroup analysis showed similar outcomes for large PFO and IPS patients to controls. CONCLUSIONS: The presence of PFO did not have a negative impact on perioperative LT outcomes.


Subject(s)
End Stage Liver Disease/surgery , Foramen Ovale, Patent/physiopathology , Liver Transplantation , Postoperative Complications , Case-Control Studies , Female , Follow-Up Studies , Foramen Ovale, Patent/diagnosis , Graft Rejection/physiopathology , Graft Survival , Humans , Incidence , Male , Middle Aged , Perioperative Care , Prognosis , Retrospective Studies , Risk Factors
2.
Transplantation ; 73(7): 1060-7, 2002 Apr 15.
Article in English | MEDLINE | ID: mdl-11965032

ABSTRACT

BACKGROUND: Expression of human complement regulating factor (hCRF) in porcine organs prevents hyperacute rejection of these organs after xenotransplantation to nonhuman primates. Experiments were designed to characterize endothelial and smooth muscle function of arteries from pigs transgenic for hCD46. METHODS: Arterial blood from outbred pigs transgenic for hCD46 expression and nontransgenic animals of the same lineage was analyzed for angiotensin-converting enzyme (ACE), C-type natriuretic peptide (CNP), and nitric oxide. Aortic endothelial cells were prepared for measurement of mRNA or activity for nitric oxide synthase (NOS). Rings cut from femoral and pulmonary arteries were suspended in organ chambers for measurement of isometric tension. RESULTS: CNP was significantly greater, ACE was similar, and nitric oxide was significantly less in plasma from transgenic compared with nontransgenic pigs. Neither mRNA nor activity of NOS differed between the groups. Endothelium-dependent relaxations to bradykinin and acetylcholine but not the calcium ionophore were shifted significantly to the left in femoral and pulmonary arteries from hCD46 transgenic pigs compared with nontransgenic pigs. The ACE-inhibitor captopril augmented relaxations similarly in both groups, but NG-monomethyl-L-arginine (L-NMMA) did not inhibit relaxations in rings from transgenic pigs. CONCLUSIONS: Data suggest that expression of hCD46 on endothelium of pigs selectively augments endothelium-dependent relaxations to bradykinin by increased release of endothelium-derived factors other than nitric oxide. There does not seem to be any change in activity of ACE or NOS with expression of the human protein. Increased relaxations to bradykinin may be beneficial in lowering vascular resistance when transgenic organs are used for xenotransplantation.


Subject(s)
Antigens, CD/physiology , Endothelium, Vascular/physiology , Membrane Glycoproteins/physiology , Angiotensin I/pharmacology , Animals , Bradykinin/pharmacology , Calcimycin/pharmacology , Captopril/pharmacology , Dose-Response Relationship, Drug , Endothelin-1/pharmacology , Humans , Male , Membrane Cofactor Protein , Natriuretic Peptide, C-Type/physiology , Nitric Oxide/pharmacology , Nitric Oxide Synthase/metabolism , Swine , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...